Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.15
-$0.76-1.81%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -41.90M | -39.15M | -31.42M | -23.42M | -13.60M |
| Total Depreciation and Amortization | 347.00K | 244.00K | 182.00K | 104.00K | 98.00K |
| Total Amortization of Deferred Charges | 111.00K | 101.00K | 92.00K | 81.00K | 78.00K |
| Total Other Non-Cash Items | 4.92M | 5.04M | 4.21M | 2.67M | 2.46M |
| Change in Net Operating Assets | -2.81M | 1.41M | 3.12M | -1.41M | 85.00K |
| Cash from Operations | -39.34M | -32.36M | -23.83M | -21.97M | -10.87M |
| Capital Expenditure | 0.00 | -375.00K | -787.00K | -340.00K | -127.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.85M | 47.74M | 64.88M | 11.63M | -87.09M |
| Cash from Investing | 17.85M | 47.37M | 64.09M | 11.29M | -87.22M |
| Total Debt Issued | 0.00 | 5.00M | 0.00 | 5.00M | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.76M | 99.89M | 510.00K | 13.00K | 264.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 19.76M | 104.89M | 510.00K | 5.01M | 264.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.73M | 119.90M | 40.78M | -5.66M | -97.83M |